Phenotypic Characterization and Heterogeneity among Modern Clinical Isolates of Acinetobacter baumannii.

Acinetobacter baumannii Gram-negative bacteria bacterial capsule capsular polysaccharide genotypes macrocolonies phenotypes transmission electron microscopy virulence factors

Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
14 02 2023
Historique:
pubmed: 9 12 2022
medline: 17 2 2023
entrez: 8 12 2022
Statut: ppublish

Résumé

Acinetobacter baumannii is an opportunistic pathogenic bacterium prioritized by WHO and CDC because of its increasing antibiotic resistance. Heterogeneity among strains represents the hallmark of A. baumannii bacteria. We wondered to what extent extensively used strains, so-called reference strains, reflect the dynamic nature and intrinsic heterogeneity of these bacteria. We analyzed multiple phenotypic traits of 43 nonredundant, modern, and multidrug-resistant, extensively drug-resistant, and pandrug-resistant clinical isolates and broadly used strains of A. baumannii. Comparison of these isolates at the genetic and phenotypic levels confirmed a high degree of heterogeneity. Importantly, we observed that a significant portion of modern clinical isolates strongly differs from several historically established strains in the light of colony morphology, cellular density, capsule production, natural transformability, and

Identifiants

pubmed: 36475894
doi: 10.1128/spectrum.03061-22
pmc: PMC9927488
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0306122

Références

Front Microbiol. 2019 Sep 24;10:2165
pubmed: 31616393
Annu Rev Genet. 2019 Dec 3;53:217-237
pubmed: 31433955
Nat Microbiol. 2019 Sep;4(9):1432-1442
pubmed: 31439928
J Bacteriol. 2015 Aug 1;197(15):2593-9
pubmed: 26013481
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0089222
pubmed: 35969073
Sci Rep. 2015 Mar 02;5:8643
pubmed: 25728466
IUBMB Life. 2011 Dec;63(12):1068-74
pubmed: 22034231
J Bacteriol. 2020 May 27;202(12):
pubmed: 32229531
Microb Genom. 2019 Oct;5(10):
pubmed: 31599224
J Appl Microbiol. 2021 Dec;131(6):2715-2738
pubmed: 33971055
PLoS Pathog. 2021 Feb 2;17(2):e1009291
pubmed: 33529209
Nature. 2006 Nov 9;444(7116):226-9
pubmed: 17086202
Carbohydr Res. 2015 Sep 2;413:12-5
pubmed: 26057991
New Microbes New Infect. 2019 Apr 16;30:100547
pubmed: 31193724
Microbiol Res. 2021 May;246:126702
pubmed: 33465557
ISME J. 2022 May;16(5):1473-1477
pubmed: 34949784
Vaccine. 2017 Mar 7;35(10):1440-1447
pubmed: 28190743
J Bacteriol. 2015 Jun 15;197(12):2027-35
pubmed: 25845845
Elife. 2014 Nov 25;3:
pubmed: 25421297
J Bacteriol. 2015 Dec 28;198(6):880-7
pubmed: 26712938
J Bacteriol. 1999 Oct;181(20):6300-5
pubmed: 10515918
APMIS. 2019 Dec;127(12):753-763
pubmed: 31512768
Microb Genom. 2022 Oct;8(10):
pubmed: 36214673
PLoS One. 2017 Aug 3;12(8):e0182139
pubmed: 28771515
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Nat Commun. 2018 Aug 27;9(1):3460
pubmed: 30150745
Front Microbiol. 2019 Jul 17;10:1601
pubmed: 31379771
J Bacteriol. 2021 Mar 23;203(8):
pubmed: 33495250
Antimicrob Agents Chemother. 2011 Jul;55(7):3534-7
pubmed: 21502628
Infect Immun. 2012 Jan;80(1):228-33
pubmed: 22083703
Infect Immun. 2017 Nov 17;85(12):
pubmed: 28947651
PLoS One. 2015 Sep 24;10(9):e0138265
pubmed: 26401654
Carbohydr Res. 2015 May 18;408:8-11
pubmed: 25816997
Nat Microbiol. 2018 May;3(5):563-569
pubmed: 29693659
Clin Microbiol Rev. 2020 May 13;33(3):
pubmed: 32404435
Genome Biol Evol. 2017 Sep 1;9(9):2292-2307
pubmed: 28934377
mBio. 2014 May 27;5(3):e01076-14
pubmed: 24865555
Database (Oxford). 2022 Nov 22;2022:
pubmed: 36412325
Int J Mol Sci. 2017 Feb 21;18(2):
pubmed: 28230771
mSphere. 2020 Jul 29;5(4):
pubmed: 32727858
Nucleic Acids Res. 2022 Jan 7;50(D1):D912-D917
pubmed: 34850947
Arch Microbiol. 2016 Jul;198(5):399-407
pubmed: 26872882
Microb Genom. 2020 Mar;6(3):
pubmed: 32118530
Infect Drug Resist. 2021 Sep 10;14:3711-3719
pubmed: 34531666
Front Microbiol. 2019 May 03;10:930
pubmed: 31130931
Nat Rev Microbiol. 2018 Feb;16(2):91-102
pubmed: 29249812
Pathogens. 2021 Aug 26;10(9):
pubmed: 34578115
Virulence. 2020 Dec;11(1):1-13
pubmed: 31878839
PLoS Pathog. 2015 Feb 13;11(2):e1004691
pubmed: 25679516
Clin Microbiol Infect. 2006 Sep;12(9):826-36
pubmed: 16882287
Antimicrob Agents Chemother. 2009 Jun;53(6):2605-9
pubmed: 19332683
Antimicrob Agents Chemother. 2010 Oct;54(10):4389-93
pubmed: 20696879
J Clin Microbiol. 2018 May 25;56(6):
pubmed: 29618504
Trends Microbiol. 2022 Feb;30(2):199-200
pubmed: 34836792
Nucleic Acids Res. 2020 Jan 8;48(D1):D561-D569
pubmed: 31722416
PLoS One. 2013 Apr 16;8(4):e62160
pubmed: 23614028
BMC Genomics. 2015 Nov 14;16:933
pubmed: 26572057
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Infect Immun. 2021 Nov 16;89(12):e0045421
pubmed: 34460288
PLoS One. 2014 Sep 23;9(9):e107833
pubmed: 25247305
Microorganisms. 2016 Aug 23;4(3):
pubmed: 27681923
mBio. 2020 Oct 6;11(5):
pubmed: 33024041
BMC Microbiol. 2020 Sep 16;20(1):285
pubmed: 32938408
Curr Opin Microbiol. 2022 Apr;66:73-78
pubmed: 35104691
mBio. 2022 Feb 22;13(1):e0263121
pubmed: 35073754
Annu Rev Microbiol. 2019 Sep 8;73:481-506
pubmed: 31206345
Genome Biol Evol. 2014 Oct 13;6(10):2866-82
pubmed: 25313016
FEMS Microbiol Rev. 2016 Jul;40(4):480-93
pubmed: 27075488
J Bacteriol. 2018 Sep 10;200(19):
pubmed: 30012729

Auteurs

Adam Valcek (A)

Microbial Resistance and Drug Discovery, VIB-VUB Center for Structural Biology, VIB, Flanders Institute for Biotechnology, Brussels, Belgium.
Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Chantal Philippe (C)

Research Unit in the Biology of Microorganisms (URBM), NARILIS, University of Namur (UNamur), Namur, Belgium.

Clémence Whiteway (C)

Microbial Resistance and Drug Discovery, VIB-VUB Center for Structural Biology, VIB, Flanders Institute for Biotechnology, Brussels, Belgium.
Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Etienne Robino (E)

Microbial Resistance and Drug Discovery, VIB-VUB Center for Structural Biology, VIB, Flanders Institute for Biotechnology, Brussels, Belgium.
Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Kristina Nesporova (K)

Microbial Resistance and Drug Discovery, VIB-VUB Center for Structural Biology, VIB, Flanders Institute for Biotechnology, Brussels, Belgium.
Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Mona Bové (M)

Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

Tom Coenye (T)

Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

Tim De Pooter (T)

Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Wouter De Coster (W)

Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Applied and Translational Neurogenomics Group, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Mojca Strazisar (M)

Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Charles Van der Henst (C)

Microbial Resistance and Drug Discovery, VIB-VUB Center for Structural Biology, VIB, Flanders Institute for Biotechnology, Brussels, Belgium.
Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH